Gout Therapeutics Market Forecast to 2030

The expected CAGR of gout therapeutics market is tend to be around 8.9% in the mentioned forecast period

As per the data by The World Bank, in 2019, non-communicable diseases caused 74% of deaths worldwide. According to numerous studies, the occurrence and incidence of gout have increased in the last few decades. Gout treatment demands both pharmacological and non-pharmacological measures. Men can be three times more likely to have gout than women as they have higher levels of uric acid most of their lives. Women reach these uric acid levels after menopause.

Request For a Sample Copy of This Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-gout-therapeutics-market

Data Bridge Market Research analyses a growth rate in the gout therapeutics market in the forecast period 2023-2030. The expected CAGR of gout therapeutics market is tend to be around 8.9% in the mentioned forecast period. The market was valued at USD 2.40 billion in 2022, and it would grow upto USD 4.75 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Gout is a type of inflammatory arthritis that is developed above the age of 40 years amongst males who are having high level of uric acid in the blood. It is more prevalent in males than females. The acid can form needle type crystals in joints and can cause serious pain, swelling and tenderness. Gout is a common form of inflammatory arthritis which is quite painful. It generally affects one joint at a time. There are times when symptoms get worse, known as flares, and then there are times when there are no symptoms termed as remission.

There have been growing collaborations between different key players that result in the market growth. For instance, in June 2021, Arrowhead Pharmaceuticals, Inc. and Horizon Therapeutics plc announced a global collaboration and license agreement for ARO-XDH. It is a previously unknown discovery-stage investigational RNA interference (RNAi) therapeutic that is being developed by Arrowhead as a potential treatment for uncontrolled gout.

NSAIDs, such as indomethacin (Indocin) and naproxen (Naprosyn), are the treatment of choice for the majority of acute gout patients. There is no data that one NSAID is superior to another. High doses of short-acting NSAIDs provide the quickest symptom relief. These medications could cause stomach upset, ulcers, or diarrhea; however, most people tolerate them well when used for a short period of time.

North America dominates the market due to the presence of key product manufacturing, high research and development and growing healthcare expenditure. Asia-Pacific is expected to account for the largest market share due to the increased incidence of evolving lifestyles related with hypertension, kidney and liver disorders.

The major players covered in the Gout Therapeutics Market report are Pfizer Inc. (U.S.), Abbvie Inc. (U.S.), Novartis AG (Switzerland), Amgen Inc. (U.S.), Merck & Co Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceuticals Industries Ltd. (Israel), AstraZeneca (U.K.), Boehringer Ingelheim International GmbH. (Germany), GSK plc (U.K.), Antares Pharma (U.S.), Astellas Pharma Inc. (Japan) among others.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:-

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:- corporatesales@databridgemarketresearch.com